Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Humana Inc.

Williams' board of directors has approved a regular dividend of $0.50 per share, or $2.00 annualized, on the company's common stock, payable on Dec. 29, 2025, to holders of record at the close of business on Dec. 12, 2025. This is a 5.3% increase from Williams' 2024 quarterly dividend of $0.4750 per share. illiams has paid a common stock dividend every quarter since 1974.
The board of directors of Eli Lilly has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on December 10, 2025, to shareholders of record at the close of business on November 14, 2025.
Cheniere Energy today announced that its Board of Directors has declared a quarterly cash dividend of $0.555 per common share, an increase of over 10% from the prior quarter, payable on November 18, 2025 to shareholders of record as of the close of business on November 7, 2025.
Humana announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on January 30, 2026 to stockholders of record as of the close of business on December 26, 2025.
The Board of Directors of Albemarle announced today that it declared a quarterly common stock dividend of $0.405 per share. The dividend, which has an annualized rate of $1.62, is payable January 2, 2026, to shareholders of record at the close of business as of December 12, 2025.
VIDEO: Daily Dividend Report: WMB,LLY,LNG,HUM,ALB
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Daily Dividend Report: WMB,LLY,LNG,HUM,ALB

UnitedHealth Group (UNH) came out with quarterly earnings of $2.92 per share, beating the Zacks Consensus Estimate of $2.75 per share. This compares to earnings of $7.15 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +6.18%. A quarter ago, it was expected that this largest U.S. health insurer would post earnings of $4.84 per share when it actually produced earnings of $4.08, delivering a surprise of -15.7%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
UnitedHealth, which belongs to the Zacks Medical - HMOs industry, posted revenues of $113.16 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.17%. This compares to year-ago revenues of $100.82 billion. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
UnitedHealth shares have lost about 27.7% since the beginning of the year versus the S&P 500's gain of 16.9%.
What's Next for UnitedHealth?
While UnitedHealth has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for UnitedHealth was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.07 on $113.87 billion in revenues for the coming quarter and $16.15 on $448.36 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - HMOs is currently in the bottom 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Humana (HUM), another stock in the same industry, has yet to report results for the quarter ended September 2025. The results are expected to be released on November 5.
This health insurer is expected to post quarterly earnings of $2.91 per share in its upcoming report, which represents a year-over-year change of -30.1%. The consensus EPS estimate for the quarter has been revised 2.3% lower over the last 30 days to the current level.
Humana's revenues are expected to be $31.98 billion, up 9.1% from the year-ago quarter.
Should You Invest in UnitedHealth Group Incorporated (UNH)?
Before you invest in UnitedHealth Group Incorporated (UNH), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

UnitedHealth Group (UNH) Beats Q3 Earnings Estimates

Healthcare plan provider Centene Corporation CNC is set to report third-quarter 2025 results on Oct. 29, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at a loss of 21 cents per shareon revenues of $47.62 billion.
The third-quarter earnings estimate remained stable over the past 60 days. The bottom-line projection indicates a year-over-year plunge of 113%. However, the Zacks Consensus Estimate for quarterly revenues suggests a year-over-year growth of 13.3%.
Image Source: Zacks Investment Research
For 2025, the Zacks Consensus Estimate for Centene’s revenues is pegged at $190.45 billion, implying a rise of 16.8% year over year. The consensus mark for 2025 EPS is pegged at $1.69, implying a decrease of 76.4%, year over year.
Centenebeat the earnings estimates in three of the last four quarters and missed once, with the average surprise being negative 5.2%. This is depicted in the figure below.
Centene Corporation Price and EPS Surprise
Q3 Earnings Whispers for Centene
Our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That’s not the case here.
CNC has an Earnings ESP of 0.00% and a Zacks Rank #5 (Strong Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
What’s Shaping Centene’s Q3 Results?
The Zacks Consensus Estimate for the company’s total commercial memberships indicates a 26.6% year-over-year increase, whereas our model estimate predicts a 23.1% growth, primarily due to growth in the commercial marketplace. Both the consensus estimate and our model estimate for Medicare PDP memberships signal nearly 17% growth from the year-ago quarter.
The Zacks Consensus Estimate projects the company’s premium growth at about 19% year over year, in line with our model forecasts. This is likely to have supported top-line growth in the to-be-reported quarter.
However, the Zacks Consensus Estimate for total membership indicates a 2.2% year-over-year decline, due to decreases in Medicaid and Medicare memberships. Both the consensus estimate and our model estimate for the company’s total Medicaid memberships indicate a nearly 2% decline from a year ago.
The consensus estimate for service revenues indicates a 7.2% fall from the year-ago quarter’s $784 million. Also, the Zacks Consensus Estimate for the company’s investment and other income indicates an 11.7% year-over-year decline from $432 million.
Moreover, following the industry trend, CNC’s medical costs are expected to have remained elevated in the third quarter. The Zacks Consensus Estimate for the total health benefits ratio is pegged at 93%, up from 89.2% in the year-ago period, meaning a reduced portion of premiums remaining in hand after paying claims. Our model estimate for total operating expenses indicates more than a 15% increase in the third quarter. These are expected to have affected the bottom line, making an earnings beat uncertain.
Stocks That Warrant a Look
While an earnings beat looks uncertain for Centene, here are some companies from the broader Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around:
Select Medical Holdings Corporation SEM has an Earnings ESP of +8.58% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Select Medical’s bottom line for the to-be-reported quarter of 18 cents per share has witnessed one upward revision against no downward movement over the past month. The consensus mark for Select Medical’s revenues is pegged at $1.32 billion.
Erasca, Inc. ERAS has an Earnings ESP of +5.66% and a Zacks Rank of 2.
The Zacks Consensus Estimate for Erasca’s bottom line for the to-be-reported quarter remained stable over the past week. Erasca’s earnings beat estimates in three of the past four quarters and met once, with an average surprise of 13%.
Humana Inc. HUM has an Earnings ESP of +4.29% and a Zacks Rank of 2.
The Zacks Consensus Estimate for Humana’s bottom line for the to-be-reported quarter is pegged at $2.91 per share, which remained stable over the past week. Humana beat earnings estimates in three of the past four quarters and missed once, with an average surprise of 9.6%.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See "2nd Wave" AI stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Can Centene's Q3 Earnings Escape Industry's Cost Headwinds?

The S&P 500 Index ($SPX) (SPY) today is up +0.32%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.18%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.33%. December E-mini S&P futures (ESZ25) are up +0.35%, and December E-mini Nasdaq futures (NQZ25) are up +0.35%.
Stock indexes are moving higher today, led by strength in energy producers after WTI crude oil jumped more than +5% when the US blacklisted state-run Rosneft PJSC and Lukoil PJSC, Russia's largest oil producers, which threatens to tighten global oil supplies. Also, Dow Inc. is up more than +11% after reporting stronger-than-expected Q3 adjusted operating Ebitda. In addition, Honeywell International is up more than +5% after reporting better-than-expected Q3 sales.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
On the negative side, Molina Healthcare is down more than -20% to lead health insurers lower after cutting its full-year adjusted EPS forecast. Also, International Business Machines is down more than -4% after reporting a smaller-than-expected increase in its Q3 hybrid cloud unit. In addition, Tesla is down more than -3% after reporting Q3 EPS below consensus.
Late Wednesday, the Trump administration announced sanctions on Rosneft PJSC and Lukoil PJSC, Russia's biggest oil producers, due to "Russia's lack of serious commitment to a peace process to end the war in Ukraine." The new sanctions could bar foreign countries or companies from conducting business with the oil companies and cut them off from much of the international financial system.
The markets are focusing on progress in US-China trade talks, as President Trump reiterated his threat on Monday to boost tariffs on Chinese goods "if there isn't a deal" by November 1. President Trump is scheduled to meet Chinese President Xi Jinping next week on the sidelines of the Asia-Pacific Economic Cooperation conference in South Korea.
The shutdown of the US government continues into its fourth week, weighing on market sentiment and delaying key economic reports. The government shutdown means delays in the release of government reports, including the last four weeks of weekly initial unemployment claims and the September payroll report. The Bureau of Labor Statistics (BLS) said the September consumer price report, which was initially scheduled to be released last Wednesday, will be released this Friday. The White House has warned that if the government shutdown lingers, it would trigger widespread dismissals of employees in government programs that don't align with President Trump's priorities. Bloomberg Economics estimates that 640,000 federal workers will be furloughed during the shutdown, which would expand jobless claims and push the unemployment rate up to 4.7%.
The markets this week will focus on earnings results as the Q3 earnings season continues. Rising corporate earnings expectations are a bullish backdrop for stocks. According to Bloomberg Intelligence, 85% of the S&P 500 companies that have reported so far have beaten forecasts, on course for the best quarter since 2021. Also, more than 22% of companies in the S&P 500 that have provided guidance for their Q3 earnings results are expected to beat analysts' expectations, the highest in a year. However, Q3 profits are expected to have risen by +7.2% y/y, the smallest increase in two years. Also, Q3 sales growth is projected to slow to +5.9% y/y from 6.4% in Q2.
The markets are pricing in a 99% chance of a -25 bp rate cut at the next FOMC meeting on Oct 28-29.
Overseas stock markets are mixed today. The Euro Stoxx 50 is up +0.17%. China's Shanghai Composite closed up +0.22%. Japan's Nikkei Stock 225 closed down -1.35%.
Interest Rates
December 10-year T-notes (ZNZ5) today are down -8 ticks. The 10-year T-note yield is up +3.4 bp to 3.984%. T-notes are under pressure today due to inflation concerns, as a +5% surge in WTI crude oil prices has boosted inflation expectations and pushed the 10-year breakeven inflation rate up to a 1-week high of 2.309%. Also, supply pressures are negative for T-notes as the Treasury will auction $26 billion of 5-year TIPS later today.
T-notes have ongoing support due to the ongoing US government shutdown, which could lead to additional job losses, reduced consumer spending, and a weakened US economy, potentially allowing the Fed to continue cutting interest rates.
European government bond yields are moving higher today. The 10-year German bund yield is up +1.6 bp to 2.579%. The 10-year UK gilt yield is up +0.8 bp to 4.425%.
Swaps are discounting a 1% chance for a -25 bp rate cut by the ECB at its next policy meeting on October 30.
US Stock Movers
Energy stocks and energy service providers are climbing today, with the price of WTI crude oil up more than +5% at a 2-week high. APA Corp (APA) is up more than +6% and Valero Energy (VLO) is up more than +5%. Also, Diamondback Energy (FANG) and Devon Energy (DVN) are up more than +4%, and Occidental Petroleum (OXY) and ConocoPhillips (COP) are up more than +3%. In addition, Halliburton (HAL), Phillips 66 (PSX), and Baker Hughes (BKR) are up more than +2%.
Quantum-computing stocks are rallying today after the Wall Street Journal reported that the firms are in talks to give the Commerce Department equity stakes in exchange for federal funding. As a result, IonQ (IONQ), Rigetti Computing (RGTI), D-Wave Quantum (QBTS), and Quantum Computing (QUBT) are up more than +6%.
Molina Healthcare (MOH) is down more than -20% to lead health insurers lower and losers in the S&P 500 after cutting its full-year adjusted EPS forecast to $14.00 from a previous estimate of $19.00, well below the consensus of $18.65. Also, Centene (CNC) and Oscar Health (OSCR) are down more than -7%. In addition, Humana (HUM) is down -2%, and Elevance Health (ELV), United Health Services (UHS), and UnitedHealth Group (UNH) are down more than -1%.
West Pharmaceutical Services (WST) is up more than +12% to lead gainers in the S&P 500 after raising its full-year adjusted EPS estimate to $7.06-$7.11 from a previous forecast of $6.65-$6.85.
Dow Inc. (DOW) is up more than +11% after reporting Q3 adjusted operating Ebitda of $868 million, well above the consensus of $759.7 million.
Las Vegas Sands (LVS) is up more than +9% after reporting Q3 net revenue of $3.33 billion, above he consensus of $3.04 billion.
Honeywell International (HON) is up more than +5% to lead gainers in the Dow Jones Industrials and Nasdaq 100 after reporting Q3 sales of $10.41 billion, stronger than the consensus of $10.15 billion.
TransUnion (TRU) is up more than +3% after reporting Q3 adjusted EPS of $1.10, better than the consensus of $1.05.
CME Group (CME) is up more than +1% after Deutsche Bank upgraded the stock to buy from hold with a price target of $300.
Roper Technologies (ROP) is down more than -7% to lead losers in the Nasdaq 100 after forecasting Q4 adjusted EPS from continuing operations $5.11 to $5.16, weaker than the consensus of $5.24.
International Business Machines (IBM) is down more than -4% to lead losers in the Dow Jones Industrials after reporting a +14% increase in its Q3 hybrid cloud unit, below the consensus of +16%.
Tesla (TSLA) is down more than -3% after reporting Q3 EPS of 50 cents, weaker than the consensus of 54 cents.
Southwest Airlines (LUV) is down by more than -3% after reporting Q3 operating revenue of $6.90 billion, below the consensus of $6.92 billion.
Tractor Supply Co (TSCO) is down more than -3% after narrowing its full-year comparable sales forecast to +1.4% to +2.4% from a previous forecast of 0% to +4.0%.
Packaging Corp (PKG) is down more than -1% after reporting Q3 adjusted EPS of $2.73, below the consensus of $2.82.
Moderna (MRNA) is down more than -4% after saying its vaccine to prevent cytomegalovirus, a common cause of birth defects, failed to meet its goal in a late-stage trial.
Earnings Reports(10/23/2025)
Alaska Air Group Inc (ALK), Allegion plc (ALLE), American Airlines Group Inc (AAL), AutoNation Inc (AN), Baker Hughes Co (BKR), Blackstone Inc (BX), Boston Beer Co Inc/The (SAM), Boyd Gaming Corp (BYD), Brunswick Corp/DE (BC), Carpenter Technology Corp (CRS), CBRE Group Inc (CBRE), CenterPoint Energy Inc (CNP), Comfort Systems USA Inc (FIX), Darling Ingredients Inc (DAR), Deckers Outdoor Corp (DECK), Digital Realty Trust Inc (DLR), Dover Corp (DOV), Dow Inc (DOW), EastGroup Properties Inc (EGP), Euronet Worldwide Inc (EEFT), First Citizens BancShares Inc/ (FCNCA), Ford Motor Co (F), Freeport-McMoRan Inc (FCX), FTI Consulting Inc (FCN), Hasbro Inc (HAS), Healthpeak Properties Inc (DOC), Honeywell International Inc (HON), Intel Corp (INTC), Iridium Communications Inc (IRDM), Kinsale Capital Group Inc (KNSL), Lazard Inc (LAZ), Millrose Properties Inc (MRP), Mohawk Industries Inc (MHK), MSC Industrial Direct Co Inc (MSM), Newmont Corp (NEM), Norfolk Southern Corp (NSC), Old Republic International Cor (ORI), PG&E Corp (PCG), Pool Corp (POOL), Popular Inc (BPOP), Roper Technologies Inc (ROP), Ryder System Inc (R), SLM Corp (SLM), Spirit AeroSystems Holdings In (SPR), SS&C Technologies Holdings Inc (SSNC), TechnipFMC PLC (FTI), Textron Inc (TXT), T-Mobile US Inc (TMUS), Tractor Supply Co (TSCO), TransUnion (TRU), Union Pacific Corp (UNP), Valero Energy Corp (VLO), VeriSign Inc (VRSN), West Pharmaceutical Services Inc (WST), Western Union Co/The (WU).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stocks Climb on Strength in Energy Producers

In the ever-evolving health insurance landscape, UnitedHealth Group Incorporated UNH and Humana Inc. HUM stand as two dominant forces. Both companies have built resilient business models rooted in Medicare Advantage (MA), pharmacy benefit management and healthcare services, pillars that will remain vital as the U.S. population continues to age.
While UnitedHealth boasts a diversified empire spanning insurance, care delivery and analytics, Humana’s focused approach to government-backed plans has cemented its leadership in the MA space. With demographic trends, utilization shifts and policy reforms reshaping the sector, investors are paying close attention to both names.
As healthcare costs rise and enrollment dynamics evolve, one critical question looms: Which insurer offers the stronger prescription for investors today? Let’s take a closer look at their fundamentals to find out which stock truly comes out on top.
The Case for UnitedHealth
With a market capitalization of $330.1 billion, UnitedHealth has long set the benchmark for scale and diversification in managed care. Its operations are divided between UnitedHealthcare, which provides insurance coverage and Optum, a fast-growing arm offering healthcare services, analytics and pharmacy benefit management. This integrated structure helps cushion the company against volatility in any one area.
In its latest reported quarter, UnitedHealth delivered revenues of $111.6 billion, up 12.9% year over year, supported by solid domestic commercial membership growth and ongoing strength in Optum Rx. However, rising medical utilization has pressured margins, especially within its MA business. The company’s medical care ratio climbed to 89.4%, up from 85.1% a year earlier, signaling higher medical costs that left a smaller share of premiums after claims.
The Optum brand continues to be a long-term growth driver, generating $67.2 billion in revenues in the last reported quarter, up 6.9% from last year. Yet, it is facing near-term pressure in its Optum Health unit. While UNH’s scale and vertical integration offer unmatched stability, growth in its Medicaid book has remained tapered. The company is currently under scrutiny over its Medicare billing practices, reimbursement methods, and Optum Rx operations.
Additionally, UNH is facing questions surrounding its handling of the loans to healthcare providers following the 2024 Change Healthcare cyberattack. From a balance sheet standpoint, UNH’s long-term debt-to-capital ratio of 43.7% exceeds Humana’s 40.8%, indicating slightly higher leverage. Its current share price also trades above its average analyst target of $363.32, implying a modest 0.3% downside risk. In contrast, Humana’s stock trades below its average target of $292.42, signaling an estimated 3% upside potential.
The Case for Humana
Though smaller in scale with a market cap of $34.2 billion, Humana has carved a niche as a Medicare Advantage specialist. The company is showing signs of stabilization, with its benefit ratio improving to 88.7% in the first half of 2025 from 89.4% a year earlier, a reflection of better cost discipline and pricing efficiency despite elevated industrywide utilization.
In the last reported quarter, Humana posted adjusted revenues of $32.4 billion, rising 10.2% year over year, fueled by strength in state-based contracts and CenterWell performance. Improving membership figures in Medicare Supplement, Group Medicare Advantage and Medicare Stand-Alone PDPs are providing some relief amid declining overall memberships.
Humana’s renewed focus on value-based care and operational efficiency is beginning to pay off. Its CenterWell primary care centers continue to expand, lowering long-term medical costs and boosting member retention through coordinated care delivery. This approach enhances profitability while ensuring sustainable growth in its footprint.
While UnitedHealth’s vast Optum network gives it size, Humana’s more agile structure allows it to adapt faster to regulatory and reimbursement changes. The company’s efforts to streamline operations, exit unprofitable segments and reinvest in Medicare Advantage growth position it favorably for the coming days.
How Do Zacks Estimates Compare for UNH & HUM?
Analysts anticipate a rebound in Humana’s 2025 earnings, with the Zacks Consensus Estimate standing at $17.05 per share, implying 5.2% year-over-year growth as its cost pressures ease and enrollment stabilizes. Over the past month, the estimate has seen one upward revision with no downward adjustments. Historically, HUM has beaten estimates in three of the last four quarters and missed once, delivering an average earnings surprise of 9.6%.
Humana Inc. Price, Consensus and EPS Surprise
For UnitedHealth, consensus forecasts 2025 EPS of $16.16, reflecting a steep 41.6% year-over-year decline. The estimate has remained unchanged over the past month, signaling limited near-term optimism. Over the last four quarters, UNH beat twice and missed twice, posting an average negative surprise of 3.3%.
UnitedHealth Group Incorporated Price, Consensus and EPS Surprise
Valuation: UNH vs. HUM
Humana trades at a forward P/E of 20.81X, below UnitedHealth’s 21.29X, offering a relative discount despite a stronger projected rebound in 2025. This valuation gap suggests investors may be underestimating Humana’s margin recovery potential and efficiency gains. HUM carries a Value Score of A.
Meanwhile, UNH’s premium multiple reflects its size and defensive appeal, but with growth moderating and cost pressures lingering, the upside appears constrained. UNH carries a Value Score of B.
Image Source: Zacks Investment Research
Price Performance Comparison
Year to date, Humana’s shares have gained 16.4%, sharply outperforming UnitedHealth’s 27.8% decline, the broader industry’s 21.7% drop and the S&P 500’s 15.6% growth. This contrast highlights improving investor confidence in Humana’s turnaround plan, cost containment and earnings visibility.
The positive price action suggests that markets are starting to recognize Humana’s repositioning efforts, while sentiment toward UnitedHealth remains muted amid uncertainty surrounding its medical cost trends and regulatory investigations.
Price Performance – UNH, HUM, Industry & S&P 500
Image Source: Zacks Investment Research
Conclusion
UnitedHealth continues to reign as the industry’s most diversified and stable player, supported by its vast Optum platform and balanced revenue streams. However, the near term looks challenging, with elevated utilization, regulatory probes and margin pressure clouding its growth trajectory.
Humana, though smaller, is regaining momentum through disciplined cost control, sharper focus on Medicare Advantage, and expanding CenterWell operations. Its leaner structure, targeted strategy, and more appealing valuation give it an edge in both recovery speed and growth potential.
In this battle of healthcare giants, Humana emerges as the healthier option to add to your portfolio; better positioned to capture the demographic tailwinds and policy-driven opportunities ahead, even though both companies currently have a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See "2nd Wave" AI stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

UNH vs. HUM: Which Healthcare Stock is the Healthier Buy Now?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Beam Therapeutics Inc. (BEAM) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Beam Therapeutics Inc. is a member of our Medical group, which includes 956 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Beam Therapeutics Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BEAM's full-year earnings has moved 1.4% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, BEAM has moved about 4% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 0.4% on average. This means that Beam Therapeutics Inc. is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Humana (HUM). The stock is up 5.4% year-to-date.
For Humana, the consensus EPS estimate for the current year has increased 4.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Beam Therapeutics Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 470 individual stocks and currently sits at #83 in the Zacks Industry Rank. This group has gained an average of 8.9% so far this year, so BEAM is slightly underperforming its industry in this area.
On the other hand, Humana belongs to the Medical - HMOs industry. This 8-stock industry is currently ranked #163. The industry has moved -24% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Beam Therapeutics Inc. and Humana as they could maintain their solid performance.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Is Beam Therapeutics (BEAM) Stock Outpacing Its Medical Peers This Year?

The S&P 500 Index ($SPX) (SPY) on Tuesday closed down -0.16%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.44%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.69%. December E-mini S&P futures (ESZ25) fell -0.20%, and December E-mini Nasdaq futures (NQZ25) fell -0.75%.
Stock indexes settled mixed on Tuesday, with the Dow Jones Industrial Average recovering from a one-month low. Stocks were pressured on Tuesday as the US-China trade conflict escalated further after China sanctioned five US units of South Korean shipbuilder Hanwha Ocean Co., in the latest in a series of tit-for-tat moves. Both countries have slapped special port fees on each other’s vessels. The moves have implications for the global economy, as vessels are responsible for moving more than 80% of international trade. Additionally, President Trump stated that he may halt trade in cooking oil from China as a retaliatory measure against China’s refusal to purchase US soybeans.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
Stock indexes recovered from their worst levels on Tuesday as bond yields declined on dovish comments from Fed Chair Powell, which reinforced expectations that the Fed will cut interest rates at the October 28-29 FOMC meeting. Fed Chair Powell said labor market perceptions remain on a downward trajectory and that the Fed may stop shrinking its balance sheet and end quantitative tightening in the coming months. The 10-year T-note yield fell -2 bp to 4.02%.
Stocks also garnered support on Tuesday on AI optimism after Walmart rose more than 4% after it announced a partnership with OpenAI to enable shoppers to browse and purchase products on ChatGPT.
The escalation of trade tensions has sparked buying of precious metals as a haven, as gold and silver rallied to new record highs on Tuesday. Also, global bond markets are the recipients of haven demand from the trade turmoil as bond yields declined worldwide. The 10-year German bund yield dropped to a 3.25-month low of 2.58% and the 10-year T-note yield fell to a 3.5-week low of 4.00%.
Tuesday’s minor economic news showed that the US Sep NFIB small business optimism index fell -2.0 to 98.8, weaker than expectations of 100.6.
Most stock indexes rallied to record highs last week on optimism that growth in the AI sector and spending on artificial intelligence will translate into corporate profits. Stocks are also underpinned by hopes that a resilient US economy and additional Fed easing will continue to support the economy.
The shutdown of the US government continues, weighing on market sentiment and delaying key economic reports. The government shutdown means delays in the release of government reports, including the last two weeks of weekly initial unemployment claims, the Aug US trade report, and the Sep nonfarm payrolls report. Last Friday, the Bureau of Labor Statistics (BLS) said that it will release the September consumer price report on October 24 if the government shutdown continues into Wednesday, when the Sep CPI report is scheduled for release. The White House has warned that if the government shutdown lingered, it would trigger widespread dismissals of employees in government programs that don’t align with President Trump’s priorities. Bloomberg Economics estimates that 640,000 federal workers will be furloughed during the shutdown, which would expand jobless claims and push the unemployment rate up to 4.7%.
The markets this week will focus on Q3 earnings results as the Q3 earnings season begins. Rising corporate earnings expectations are a bullish backdrop for stocks. According to Bloomberg Intelligence, more than 22% of companies in the S&P 500 provided guidance for their Q3 earnings results that are expected to beat analysts’ expectations, the highest in a year. However, Q3 profits are expected to have risen by +7.2%, the smallest increase in two years. Also, Q3 sales growth is projected to slow to +5.9% from 6.4% in Q2.
The markets are pricing in a 98% chance of a -25 bp rate cut at the next FOMC meeting on Oct 28-29.
Overseas stock markets settled lower on Tuesday. The Euro Stoxx 50 fell to a 2-week low and closed down -0.29%. China’s Shanghai Composite closed down -0.62%. Japan’s Nikkei Stock 225 dropped to a 1-week low and closed down sharply by -2.58%.
Interest Rates
December 10-year T-notes (ZNZ5) on Tuesday closed up +8 ticks. The 10-year T-note yield fell -1.5 bp to 4.017%. Dec -T-notes rallied to a 3.5-week high on Tuesday, and the 10-year T-note yield fell to a 3.5-week low of 3.998%. The escalation of the US-China trade conflict sparked safe-haven buying of government debt securities. Also, falling inflation expectations are supportive for T-notes after the 10-year breakeven inflation rate fell to a 3.25-month low on Tuesday at 2.299%. T-notes also have support amid concerns about the ongoing US government shutdown, which could lead to additional job losses, reduced consumer spending, and a weakened US economy, potentially allowing the Fed to continue cutting interest rates.
European government bond yields moved lower on Tuesday. The 10-year German bund yield dropped to a 3.25-month low of 2.583% and finished down -2.6 bp at 2.610%. The 10-year UK gilt yield fell to a 2-month low of 4.570% and finished down -6.8 bp to 4.590%.
The German Oct ZEW expectations of economic growth survey rose +2.0 to 39.3, weaker than expectations of 41.1.
ECB President Lagarde said the Eurozone economy is “in a good place” as risks to the economic outlook are more balanced and the Eurozone economy has been relatively resilient to tariffs.
UK Aug employment rose by +91,000 in the 3-months ending August, which was weaker than expectations of +125,000. The ILO unemployment rate rose +0.1 to a 4.25-year high of 4.8% in the 3-months ending August, showing a weaker labor market than expectations of no change at 4.7%.
Swaps are discounting a 2% chance for a -25 bp rate cut by the ECB at its next policy meeting on October 30.
US Stock Movers
Chipmakers and AI infrastructure stocks retreated on Tuesday, weighing on the overall market. Arista Networks (ANET) closed down more than -5% to lead losers in the S&P 500, and Intel (INTC) closed down more than -4%. Also, Broadcom (AVGO), Marvell Technology (MRVL), Dell Technologies (DELL), Super Micro Computer (SMCI), and Micron Technology (MU) closed down more than -3%. In addition, ARM Holdings Plc (ARM) closed down more than -2%, and ON Semiconductor (ON) closed down more than-1%.
The Magnificent Seven technology stocks were mostly lower on Tuesday, a negative factor for the broader market. Nvidia (NVDA) closed down more than -4%, and Tesla (TSLA), Amazon.com (AMZN), and Meta Platforms (META) closed down more than -1%. In addition, Microsoft (MSFT) closed down -0.09%.
Humana (HUM) closed down more than -3% after it lost a lawsuit against the US government that sought to undo cuts to the 2026 bonus payments it receives from the Medicare Advantage program.
Salesforce (CRM) closed down by more than -3% after Northland Securities downgraded the stock to market perform from outperform.
Goldman Sachs (GS) closed down more than -2% after reporting Q3 equities sales and trading revenue of $3.74 billion, below the consensus of $3.94 billion.
CyberArk Software (CYBR) closed down more than -2% after Barclays downgraded the stock to equal weight from overweight.
JPMorgan Chase (JPM) closed down more than -1% despite raising its full-year net interest income estimate after CEO Dimon said he sees some softness in the US economy.
Navitas Semiconductor (NVTS) closed up more than +26% after unveiling its 100 V GaN FETs, 650 V GaN, and high voltage SIC devices for Nvidia’s 800 VDC AI factory architecture. This will enable direct conversion from 13.8 kVAC utility power to 88 VDC within the data center power room.
Polaris Inc. (PII) closed up more than +14% after saying it will separate Indian Motorcycle from its portfolio into a standalone company and enter into a definitive agreement to sell a majority stake to Carolwood LP.
Wells Fargo & Co. (WFC) closed up more than +7% to lead gainers in the S&P 500 after reporting Q3 revenue of $21.44 billion, above the consensus of $21.16 billion.
Walmart (WMT) closed up more than +4% to lead gainers in the Dow Jones Industrials after announcing that it was teaming up with OpenAI to enable shoppers to browse and purchase products on ChatGPT.
Caterpillar (CAT) closed up more than +4% after JPMorgan Chase raised its price target on the stock to $650 from $505, citing expectations for accelerating revenue growth.
HP Inc (HPQ) closed up more than +4% after HSBC upgraded the stock to buy from hold with a price target of $30.
Domino’s Pizza (DPZ) closed up more than +3% after reporting Q3 total domestic stores comparable sales growth of 5.2%, which is better than the consensus of 4.28%.
Earnings Reports(10/15/2025)
Abbott Laboratories (ABT), ASML Holding NV (ASML), Bank of America Corp (BAC), Citizens Financial Group Inc (CFG), First Horizon Corp (FHN), First Industrial Realty Trust (FR), JB Hunt Transport Services Inc (JBHT), Morgan Stanley (MS), Pinnacle Financial Partners Inc (PNFP), PNC Financial Services Group Inc (PNC), Progressive Corp/The (PGR), Prologis Inc (PLD), Rexford Industrial Realty Inc (REXR), Synchrony Financial (SYF), Synovus Financial Corp (SNV), United Airlines Holdings Inc (UAL).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Trade Jitters Weigh on Stocks

In trading on Tuesday, shares of Humana Inc. (Symbol: HUM) crossed below their 200 day moving average of $261.54, changing hands as low as $261.42 per share. Humana Inc. shares are currently trading off about 1.9% on the day. The chart below shows the one year performance of HUM shares, versus its 200 day moving average:
Looking at the chart above, HUM's low point in its 52 week range is $206.87 per share, with $315.3482 as the 52 week high point — that compares with a last trade of $262.09. The HUM DMA information above was sourced from TechnicalAnalysisChannel.com
Free Report: Top 8%+ Dividends (paid monthly)
Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average »
Also see:
Waste Management Dividend Stocks
TISI YTD Return
NNN Dividend Growth Rate
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Two Hundred Day Moving Average Cross - HUM

On Thursday, the Centers for Medicare & Medicaid Services (“CMS”) released the 2026 Star Ratings for Medicare Advantage Prescription Drug (“MAPD”) plans. The five-star rating system evaluates Medicare health care and drug plans to ensure they meet CMS’ quality standards, with plans rated four stars or higher qualifying for bonus payments. CVS Health’s CVS insurer, Aetna, continues to rank among the top tier of large, publicly traded companies, supported by high-quality performance across several of its largest Medicare Advantage contracts. More than 81% of Aetna MA members are in plans rated 4.0 stars or higher, with more than 63% of members in a 4.5-star plan for 2026.
CVS’ key rivals, Humana HUM and UnitedHealth Group UNH, had previously reported preliminary 2026 Star Ratings data. Humana has nearly 20% of its members enrolled in plans rated 4 stars and above, with 14% of members in 4.5-star plans. The company’s average Star rating of 3.61 is consistent with last year’s levels. On the other hand, UnitedHealth Group estimated that it would have approximately 78% of its members in four-star or higher plans. According to Reuters, citing Oppenheimer analysts, both insurers’ final star ratings were in line with their prior expectations.
CVS Health Stock Price Performance
CVS shares opened 1.6% higher on Oct. 10 following the after-hours announcement and ended the session at $77.90. The stock’s impressive year-to-date run now extends to 73.5%, outpacing both the industry’s 1.5% decline and the Medical sector’s modest 0.1% gains. In the same time frame, Humana shares rose 10.4%, while UnitedHealth stock declined 29.9%.
CVS’ YTD Price Performance
Image Source: Zacks Investment Research
Technical Indicator for CVS
CVS shares are now trading above the 50-day and 200-day moving averages, indicating a bullish trend.
Image Source: Zacks Investment Research
A Peek Into Aetna’s 2026 MA Plans
Aetna has unveiled the 2026 MA Plans centering around three key elements — access, simplicity and care. The company’s 2026 MADP plans will be available across 43 states and Washington, D.C., covering nearly 57 million Medicare-eligible beneficiaries. Key highlights include a $2,100 maximum annual out-of-pocket for covered prescription drugs and affordable SilverScript prescription drug plan coverage.
In every county where plans are available, Aetna provides a $0 monthly premium plan. These also come with $0 copays for Tier 1 drugs at in-network pharmacies and include dental, vision and hearing benefits, along with a SilverSneakers fitness membership. Aetna estimates that 82% of the Medicare-eligible beneficiaries will have access to a $0 premium MA plan.
Further, eligible members can use the Extra Benefits Card, powered by CVS Health’s OTC Health Solutions, on certain services and products at CVS stores and at more than 70,000 additional participating locations. Aetna offers certain in-network services at no additional costs, including $0 copays for annual physicals, colonoscopies, mammograms, routine eye and hearing exams, and $0 copays for primary care visits and labs for some plans. All MA plans include an annual Healthy Home Visit from a licensed Signify Health clinician at no extra cost.
In 2026, Aetna is broadening its Special Needs Plans (SNPs), which provide additional targeted benefits to eligible members. Chronic Condition SNPs (C-SNPs) will expand to 18 states, including 16 new ones. Dual Eligible (D-SNPs) will grow to 119 new counties, with all members receiving a monthly allowance on an Extra Benefits Card for approved over-the-counter products.
Innovation-Driven Aetna Boosts Optimism for CVS
Earlier this year, Aetna introduced an approach to bundling approvals for prior authorizations for certain cancer-related scans and tests, making it one upfront approval instead of multiple approvals over months. The move builds on CVS’ years-long effort to simplify and reduce unnecessary complexities in health care to make critical medications available more quickly. Currently, Aetna has one of the shortest lists of treatments and procedures that require prior authorization, approving more than 95% eligible requests within 24 hours.
In addition, Aetna’s Clinical Collaboration program is on track to be implemented in 10 hospitals by the end of 2025. The program helps reduce the standard 30-day readmission rates and emergency room visits while easing the administrative load on hospitals and clinical personnel. As part of CVS Health’s $20 billion multi-year digital health care investment, Aetna rolled out Aetna Care Paths, a first-to-market care option available within the Aetna Health app.
CVS’ Valuation Metrics
CVS currently trades at a forward five-year price/earnings (P/E) of 11.17X, below the industry average of 14.95X, UnitedHealth Group’s 20.71X and Humana’s 19.62X. However, the valuation appears premium in comparison to CVS’ five-year median of 9.73X.
CVS Health’s 5-Year P/E
Image Source: Zacks Investment Research
What’s Pressuring CVS Health?
The company’s retail pharmacy, specialty pharmacy and long-term care pharmacy (LTC) operations are facing ongoing reimbursement pressures from competition, client demands for lower prices, generic drug pricing, earlier-than-expected generic drug introductions and network reimbursement challenges. Increased utilization trends are also expected to continue exerting pressure on CVS’ Healthcare Benefits segment and its healthcare delivery assets throughout the remainder of 2025.
Additionally, legal issues are mounting for CVS Health. A federal court ordered its pharmacy benefit manager (PBM), Caremark, to pay nearly $290 million in damages following a decade-long allegation of overcharging Medicare for prescription drugs. More recently, the Omnicare LTC business filed for Chapter 11 bankruptcy after receiving a $949 million federal penalty related to fraudulent billing of drugs.
Our Take on CVS Stock
Aetna’s latest Star Ratings success emphasizes its focus on improving health outcomes for its MA members. Its 2026 MA plans aim to provide access to affordable, personalized care. Innovations to simplify the healthcare journey further strengthen CVS’ long-term outlook. Though ongoing reimbursement challenges and legal setbacks could affect results, the stock’s impressive YTD gains and attractive valuation make it a solid hold for existing CVS investors. However, prospective buyers should wait for a better entry point.
CVS carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

CVS' Aetna Wins Big on 2026 MA Star Ratings: How to Play the Stock?

Fintel reports that on October 10, 2025, B of A Securities maintained coverage of Humana (NYSE:HUM) with a Neutral recommendation.
Analyst Price Forecast Suggests 7.84% Upside
As of September 30, 2025, the average one-year price target for Humana is $301.97/share. The forecasts range from a low of $252.50 to a high of $361.20. The average price target represents an increase of 7.84% from its latest reported closing price of $280.02 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Humana is 116,769MM, a decrease of 5.15%. The projected annual non-GAAP EPS is 36.17.
What is the Fund Sentiment?
There are 1,855 funds or institutions reporting positions in Humana. This is an increase of 1 owner(s) or 0.05% in the last quarter. Average portfolio weight of all funds dedicated to HUM is 0.27%, an increase of 1.27%. Total shares owned by institutions decreased in the last three months by 0.12% to 138,918K shares. The put/call ratio of HUM is 0.64, indicating a bullish outlook.
What are Other Shareholders Doing?
Dodge & Cox holds 11,353K shares representing 9.44% ownership of the company. In its prior filing, the firm reported owning 10,755K shares , representing an increase of 5.26%. The firm decreased its portfolio allocation in HUM by 3.85% over the last quarter.
DODGX - Dodge & Cox Stock Fund holds 7,552K shares representing 6.28% ownership of the company. In its prior filing, the firm reported owning 7,180K shares , representing an increase of 4.91%. The firm decreased its portfolio allocation in HUM by 5.72% over the last quarter.
Pzena Investment Management holds 4,077K shares representing 3.39% ownership of the company. In its prior filing, the firm reported owning 3,829K shares , representing an increase of 6.08%. The firm decreased its portfolio allocation in HUM by 9.60% over the last quarter.
Eagle Capital Management holds 3,949K shares representing 3.28% ownership of the company. In its prior filing, the firm reported owning 3,143K shares , representing an increase of 20.41%. The firm increased its portfolio allocation in HUM by 4.89% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,887K shares representing 3.23% ownership of the company. In its prior filing, the firm reported owning 3,810K shares , representing an increase of 1.98%. The firm decreased its portfolio allocation in HUM by 15.90% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	25.99 23.75
Price/Sales	0.27 3.01
P/B	1.90 2.20
P/FCF	13.07 18.30

Indicator	TTM Median
ROE	7.21 25.41
ROA	2.45 6.00
ROI	4.23 9.66
Net Worth	31.35 0.20
Quick Ratio	0.00 1.71
Current Ratio	1.76 2.83

Indicator	TTM Median
Net Profit Margin	1.02 10.25
Operating Margin	2.18 14.24
Gross Margin	14.52 68.59
Return on tangible equity	16.86 53.53

Indicator	TTM Median
EPS	11.58 0.37
EPS Forecast	9.98 0.37
Revenue	29.21B 16.00M
Gross Profit	3.83B —
EBITDA	0.00 —

Humana Inc.

TTM metrics for the latest quarter under IFRS and their historical dynamics

Valuation

Debts

Efficiency

Other ratios

Revenue